Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer

Yanghee Woo; Vincent Reid; Kaitlyn J. Kelly; Diane Carlson; Zhenkun Yu; Yuman Fong

doi:10.1016/j.omto.2019.11.003

Back

Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer

Journal article

Open access

Peer reviewed

Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer

Yanghee Woo, Vincent Reid, Kaitlyn J. Kelly, Diane Carlson, Zhenkun Yu and Yuman Fong

Molecular therapy. Oncolytics, Vol.16, pp.1-6

03/27/2020

DOI: 10.1016/j.omto.2019.11.003

PMCID: PMC6940689

PMID: 31909180

Files and links (1)

url

https://doi.org/10.1016/j.omto.2019.11.003View

Published (Version of record) Open Access

Abstract

Early detection and timely treatment of precancerous lesions are hallmarks of successful strategies to prevent deaths due to cancer. Oncolytic viruses are a group of promising anti-cancer agents with wide-ranging experimental and clinical efficacy against solid tumors. Previously, we have shown that NV1066, an oncolytic herpes simplex-1 virus encoding enhanced green fluorescent protein, selectively infects, replicates in, and kills various cancer types. In this study, we sought to determine whether this oncolytic agent can treat precancerous lesions to prevent cancer formation. Using an oral chemical carcinogenesis model in hamsters, we assessed the ability of NV1066 to infect precancerous and cancerous lesions. NV1066 consistently infected dysplastic cells, carcinoma in situ, and squamous cell carcinoma. Animals receiving an intramucosal injection of NV1066 for 7 weeks showed significantly fewer (3-fold) and smaller (4-fold) lesions compared to animals that did not receive viral treatment. Results indicate that infectivity might be dependent on the herpes simplex virus 1 receptor, nectin-1. This study demonstrates that not only can NV1066 treat oral squamous cell carcinoma, but it can also infect and treat premalignant lesions, thus delaying cancer progression. Overall, our study shows the potential of the oncolytic virus NV1066 as a cancer prevention tool.

Life Sciences & Biomedicine

Medicine, Research & Experimental

Oncology

Research & Experimental Medicine

Science & Technology

Details

Title: Subtitle: Oncolytic Herpes Simplex Virus Prevents Premalignant Lesions from Progressing to Cancer
Creators: Yanghee Woo - Memorial Sloan Kettering Cancer Center
Vincent Reid - Memorial Sloan Kettering Cancer Center
Kaitlyn J. Kelly - Memorial Sloan Kettering Cancer Center
Diane Carlson - Memorial Sloan Kettering Cancer Center
Zhenkun Yu - Memorial Sloan Kettering Cancer Center
Yuman Fong - Memorial Sloan Kettering Cancer Center
Resource Type: Journal article
Publication Details: Molecular therapy. Oncolytics, Vol.16, pp.1-6
DOI: 10.1016/j.omto.2019.11.003
PMID: 31909180
PMCID: PMC6940689
NLM abbreviation: Mol Ther Oncolytics
ISSN: 2372-7705
eISSN: 2372-7705
Publisher: Elsevier
Number of pages: 6
Grant note: R01CA75416 / National Institutes of Health; United States Department of Health & Human Services; National Institutes of Health (NIH) - USA Flight Attendant Medical Research Institute (FAMRI) Mr. William H. Goodwin and Mrs. Alice Goodwin and the Commonwealth Foundation for Cancer Research grant - The Experimental Therapeutics Center of Memorial Sloan Kettering Cancer Center
Language: English
Date published: 03/27/2020
Academic Unit: Surgery
Record Identifier: 9984322938202771

Metrics

29 Record Views

6 Times Cited - Web of Science